Advertisement

The CHA2DS2-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation

      A recent study suggested that the CHA2DS2-VASc score can risk stratify heart failure (HF) patients without atrial fibrillation (AF) for stroke. We performed a retrospective analysis using the national Veteran Affairs database to externally validate the findings. Crude incidence rates of end points were calculated. A Cox proportional model was used to study the association between the CHA2DS2-VASc score and outcomes. In HF patients with AF (n = 17,481) and without AF (n = 36,935), the 1 year incidence rate for ischemic stroke, thromboembolism, thromboembolism (without MI), and death were 2.7 and 2.0%; 10.3 and 7.9%; 4.1 and 3.1%; and 19.2 and 26.0%, respectively, with higher rates with increasing CHA2DS2-VASc scores both with and without AF. CHA2DS2-VASc score predicted strokes in HF patients without AF (1-year C-statistic 0.62, 95% CI 0.60-0.64; NPV 85.4%, 95% CI 83.4-87.4%) with similar predictive ability to those with AF (C-statistic 0.59, 95% CI 0.56-0.62; NPV 86.4%, 95% CI 82.6-90.2%). Among patients with HF, there was an increased risk of stroke, thromboembolism, and death with increasing CHA2DS2-VASc scores regardless of AF status. Our findings support the use of the CHA2DS2-VASc score as a prognostic tool in HF.
      To read this article in full you will need to make a payment

      REFERENCES

        • Dunkman WB
        • Johnson GR
        • Carson PE
        • Bhat G
        • Farrell L
        • Cohn JN
        Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
        Circulation. 1993; 87 (accessed 10/23/2018): VI94-V101
        • Freudenberger RS
        • Hellkamp AS
        • Halperin JL
        • Poole J
        • Anderson J
        • Johnson G
        • Mark DB
        • Lee KL
        • Bardy GH
        • SCD-HeFT Investigators
        Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
        Circulation. 2007; 115: 2637-2641https://doi.org/10.1161/CIRCULATIONAHA. 106.661397
        • Alberts VP
        • Bos MJ
        • Koudstaal PJ
        • Hofman A
        • Witteman JCM
        • Stricker BHC
        • Breteler MMB
        Heart failure and the risk of stroke: the Rotterdam study.
        Eur J Epidemiol. 2010; 25: 807-812https://doi.org/10.1007/s10654-010-9520-y
        • Lip GYH
        • Nieuwlaat R
        • Pisters R
        • Lane DA
        • Crijns HJGM
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; https://doi.org/10.1378/chest.09-1584
        • Abdul-Rahim AH
        • Perez A-C
        • Fulton RL
        • Jhund PS
        • Latini R
        • Tognoni G
        • Wikstrand J
        • Kjekshus J
        • Lip GYH
        • Maggioni AP
        • Tavazzi L
        • Lees KR
        • McMurray JJV
        Risk of stroke in chronic heart failure patients without atrial fibrillation.
        Circulation. 2015; 131: 1486-1494https://doi.org/10.1161/CIRCULATIONAHA.114.013760
        • January CT
        • Wann LS
        • Calkins H
        • Chen LY
        • Cigarroa JE
        • Cleveland Jr., JC
        • Ellinor PT
        • Ezekowitz MD
        • Field ME
        • Furie KL
        • Heidenreich PA
        • Murray KT
        • Shea JB
        • Tracy CM
        • Yancy CW
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
        Circulation. 2019; 140: e125-e151https://doi.org/10.1161/CIR.0000000000000665
        • Melgaard L
        • Gorst-Rasmussen A
        • Lane DA
        • Rasmussen LH
        • Larsen TB
        • Lip GYH
        Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation.
        JAMA. 2015; 314: 1030-1038https://doi.org/10.1001/jama.2015.10725
        • Wolsk E
        • Lamberts M
        • Hansen ML
        • Blanche P
        • Køber L
        • Torp-Pedersen C
        • Lip GYH
        • Gislason G
        Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study.
        Eur J Heart Fail. 2015; 17: 828-836https://doi.org/10.1002/ejhf.309
        • Reiffel JA
        Complexities in the atrial fibrillation-stroke relationship: improving comprehension of temporal discordance, magnitude synergism, and subclinical atrial fibrillation – three sources of consternationfor physicians who care for patients with atrial fibrillation.
        J Atr Fibrillation. 2018; 11: 2100https://doi.org/10.4022/jafib.2100
        • Blanche P
        • Dartigues J-F
        • Jacqmin-Gadda H
        Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks.
        Stat Med. 2013; 32: 5381-5397https://doi.org/10.1002/sim.5958
        • Ozenne B
        • Sørensen AL
        • Scheike T
        • Torp-Pedersen C
        • Gerds TA
        riskRegression: predicting the risk of an event using Cox regression models.
        R J. 2017; 9 (Available at:) (Accessed May 1, 2020): 440-460
        • Ham HA van den
        • Klungel OH
        • Singer DE
        • Leufkens HGM
        • Staa TP van
        Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a National Primary Care Database.
        J Am Coll Cardiol. 2015; 66: 1851-1859https://doi.org/10.1016/j.jacc.2015.08.033
        • Goldberger JJ
        • Arora R
        • Green D
        • Greenland P
        • Lee DC
        • Lloyd-Jones DM
        • Markl M
        • Ng J
        • Shah SJ
        Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate.
        Circulation. 2015; 132: 278-291https://doi.org/10.1161/CIRCULATIONAHA.115.016795
        • Sanders P
        • Morton JB
        • Davidson NC
        • Spence SJ
        • Vohra JK
        • Sparks PB
        • Kalman JM
        Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans.
        Circulation. 2003; 108: 1461-1468https://doi.org/10.1161/01.CIR.0000090688.49283.67
        • Kottkamp H
        Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy.
        Eur Heart J. 2013; 34: 2731-2738https://doi.org/10.1093/eurheartj/eht194
        • Calenda BW
        • Fuster V
        • Halperin JL
        • Granger CB
        Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy.
        Nat Rev Cardiol. 2016; 13: 549-559https://doi.org/10.1038/nrcardio.2016.106
        • Diederichsen SZ
        • Haugan KJ
        • Brandes A
        • Lanng MB
        • Graff C
        • Krieger D
        • Kronborg C
        • Holst AG
        • Køber L
        • Højberg S
        • Svendsen JH
        Natural history of subclinical atrial fibrillation detected by implanted loop recorders.
        J Am Coll Cardiol. 2019; 74: 2771-2781https://doi.org/10.1016/j.jacc.2019.09.050
        • Kaplan RM
        • Koehler J
        • Ziegler PD
        • Sarkar S
        • Zweibel S
        • Passman RS
        Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score.
        Circulation. 2019; 140: 1639-1646https://doi.org/10.1161/CIRCULATIONAHA.119.041303
        • Cleland JGF
        • Findlay I
        • Jafri S
        • Sutton G
        • Falk R
        • Bulpitt C
        • Prentice C
        • Ford I
        • Trainer A
        • Poole-Wilson PA
        The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
        Am Heart J. 2004; 148: 157-164https://doi.org/10.1016/j.ahj.2004.03.010
        • Cokkinos DV
        • Haralabopoulos GC
        • Kostis JB
        • Toutouzas PK
        • HELAS investigators
        Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.
        Eur J Heart Fail. 2006; 8: 428-432https://doi.org/10.1016/j.ejheart.2006.02.012
        • Eckman MH
        • Singer DE
        • Rosand J
        • Greenberg SM
        Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.
        Circ Cardiovasc Qual Outcomes. 2011; 4: 14-21https://doi.org/10.1161/CIRCOUTCOMES.110.958108
        • Eikelboom JW
        • Connolly SJ
        • Bosch J
        • Dagenais GR
        • Hart RG
        • Shestakovska O
        • Diaz R
        • Alings M
        • Lonn EM
        • Anand SS
        • Widimsky P
        • Hori M
        • Avezum A
        • Piegas LS
        • Branch KRH
        • Probstfield J
        • Bhatt DL
        • Zhu J
        • Liang Y
        • Maggioni AP
        • Lopez-Jaramillo P
        • O'Donnell M
        • Kakkar AK
        • Fox KAA
        • Parkhomenko AN
        • Ertl G
        • Störk S
        • Keltai M
        • Ryden L
        • Pogosova N
        • Dans AL
        • Lanas F
        • Commerford PJ
        • Torp-Pedersen C
        • Guzik TJ
        • Verhamme PB
        • Vinereanu D
        • Kim J-H
        • Tonkin AM
        • Lewis BS
        • Felix C
        • Yusoff K
        • Steg PG
        • Metsarinne KP
        • Cook Bruns N
        • Misselwitz F
        • Chen E
        • Leong D
        • Yusuf S
        • COMPASS Investigators
        Rivaroxaban with or without aspirin in stable cardiovascular disease.
        N Engl J Med. 2017; 377: 1319-1330https://doi.org/10.1056/NEJMoa1709118
        • Beyer C
        • Wildauer M
        • Feuchtner G
        • Friedrich G
        • Hintringer F
        • Stühlinger M
        • Plank F
        Relationship of anticoagulant therapies on coronary plaque progression.
        JACC Cardiovasc Imaging. 2020; 13: 169-170https://doi.org/10.1016/j.jcmg.2019.07.021
        • Brandes A
        • Deirdre A
        • Lebeau J-P
        • Lettino M
        • Lip GYH
        • Pinto FJ
        • Thomas GN
        • Valgimigli M
        • Van Gelder IC
        • Van Putte BP
        • Others
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2020; (Available at:) (accessed 09/07/2020)https://doi.org/10.1093/eurheartj/ehaa612
        • Harold Rivner
        • Juan Lopez
        • Manuel Rivera
        • Fei Tang
        • Alex Velasquez
        • Litsa K Lambrakos
        • Raul D Mitrani
        • Jeffrey J Goldberger
        • Marzouka George
        D-PO01-009: the risk of stroke in atrial fibrillation with heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.
        Heart Rhythm. 2020; 17 (Available at:) (accessed 05/06/2020): S87-S200
        • Cozzolino F
        • Montedori A
        • Abraha I
        • Eusebi P
        • Grisci C
        • Heymann AJ
        • Lombardo G
        • Mengoni A
        • Orso M
        • Ambrosio G
        A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project.
        PLoS One. 2019; 14e0218919https://doi.org/10.1371/journal.pone.0218919
        • Pullicino PM
        • Halperin JL
        • Thompson JL
        Stroke in patients with heart failure and reduced left ventricular ejection fraction.
        Neurology. 2000; 54: 288-294https://doi.org/10.1212/wnl.54.2.288
        • Li L
        • Yiin GS
        • Geraghty OC
        • Schulz UG
        • Kuker W
        • Mehta Z
        • Rothwell PM
        • Oxford Vascular Study
        Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study.
        Lancet Neurol. 2015; 14: 903-913https://doi.org/10.1016/S1474-4422(15)00132-5
        • Glotzer TV
        • Daoud EG
        • Wyse DG
        • Singer DE
        • Ezekowitz MD
        • Hilker C
        • Miller C
        • Qi D
        • Ziegler PD
        The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
        Circ Arrhythm Electrophysiol. 2009; 2: 474-480https://doi.org/10.1161/CIRCEP.109.849638
        • Healey JS
        • Connolly SJ
        • Gold MR
        • Israel CW
        • Van Gelder IC
        • Capucci A
        • Lau CP
        • Fain E
        • Yang S
        • Bailleul C
        • Morillo CA
        • Carlson M
        • Themeles E
        • Kaufman ES
        • Hohnloser SH
        • ASSERT Investigators
        Subclinical atrial fibrillation and the risk of stroke.
        N Engl J Med. 2012; 366: 120-129https://doi.org/10.1056/NEJMoa1105575